CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 48 enrolled
Drug / intervention
Rohto (r) Hydra +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02985827
NCT02985827Phase 4Completed

An Open-Label, Single-Center Study to Evaluate Symptom Response and Tear Film Cooling Dynamics of Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)

ORA, Inc.·interventional·Posted Dec 7, 2016·Updated Jun 27, 2023

In Brief

A Phase 4 clinical trial evaluating Rohto (r) Hydra and Systane (r) Ultra for Dry Eye. Completed, enrolled 48 participants.

Detailed Summary

The purpose of the study is to analyze the sensation to eye drops containing menthol in people with healthy eyes and in people with dry eyes. This study also examines the temperature of your eye using an Infrared Camera.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 7, 2016
Enrollment StartDec 1, 2015
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 9.6 years ago

Interventions

Rohto (r) Hydradrug

Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose

Systane (r) Ultradrug

Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose